Kailera Therapeutics grants options to director

Kailera Therapeutics, Inc. reported that director John F. Milligan received a grant of stock options covering 38,300 shares of common stock.

Accepted by SEC EDGAR 04/20/2026 - 05:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. reported that director John F. Milligan received a grant of stock options covering 38,300 shares of common stock. The options have an exercise price of $16.00 per share and expire on April 16, 2036.

The options vest and become exercisable in full on April 16, 2027, as long as Milligan continues to serve the company through that date. Following this grant, he holds stock options for 38,300 underlying shares directly.

Insider Trade Summary

Grant/Award: 38,300 shares

Grant/Award 1 txn

Insider MILLIGAN JOHN F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,300	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 38,300 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 38,300 contracts (Direct)

Footnotes (1)

1. F1. The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Option grant size: 38,300 options Exercise price: $16.00 per share Underlying shares: 38,300 shares +3 more

6 metrics

Option grant size 38,300 options Stock Option (right to buy) granted to director

Exercise price $16.00 per share Price to exercise options into common stock

Underlying shares 38,300 shares Common stock underlying granted options

Vesting date April 16, 2027 Options vest 100% on this date

Expiration date April 16, 2036 Options lapse after this date

Options held after grant 38,300 options Total options following transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 16.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-04-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did director John F. Milligan receive in this KLRA Form 4 filing?

John F. Milligan received a grant of stock options for 38,300 shares of Kailera Therapeutics common stock. These options represent a compensation award rather than an open-market purchase or sale of existing shares.

What is the exercise price of John F. Milligan’s Kailera Therapeutics options?

The stock options granted to John F. Milligan have an exercise price of $16.00 per share. This is the price he must pay per share to convert the options into Kailera Therapeutics common stock once they are vested.

When do John F. Milligan’s KLRA stock options vest and become exercisable?

The options vest and become exercisable as to 100% of the underlying 38,300 shares on April 16, 2027. Vesting is conditioned on Milligan’s continued service with Kailera Therapeutics through that vesting date.

When do the Kailera Therapeutics stock options granted to Milligan expire?

The options granted to John F. Milligan expire on April 16, 2036. After that date, any unexercised options will lapse and can no longer be used to purchase Kailera Therapeutics common stock at the $16.00 exercise price.

How many Kailera Therapeutics option shares does Milligan hold after this grant?

After this grant, John F. Milligan holds stock options covering 38,300 underlying shares of Kailera Therapeutics common stock. All of these options were acquired in this single derivative transaction reported in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILLIGAN JOHN F

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	04/16/2026		A		38,300		(1)	04/16/2036	Common Stock	38,300	$0	38,300	D

Explanation of Responses:

1. The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.

	/s/ John Mei, Attorney-in-fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)